Patent classifications
C07C279/28
ARGININE GINGIPAIN INHIBITORS
Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.
ARGININE GINGIPAIN INHIBITORS
Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.
Integrated synthesis of commodity chemicals from waste plastic
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a furnace to yield an effluent gas entraining a carbide of the active metal; cooling the effluent gas entraining the carbide of the active metal; introducing nitrogen into the cooled effluent gas entraining the carbide of the active metal, to yield a cyanamide of the active metal and elemental carbon; and acidically hydrolyzing the cyanamide of the active metal to yield a cyanamide compound and a salt of the active metal.
Integrated synthesis of commodity chemicals from waste plastic
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a furnace to yield an effluent gas entraining a carbide of the active metal; cooling the effluent gas entraining the carbide of the active metal; introducing nitrogen into the cooled effluent gas entraining the carbide of the active metal, to yield a cyanamide of the active metal and elemental carbon; and acidically hydrolyzing the cyanamide of the active metal to yield a cyanamide compound and a salt of the active metal.
Compounds and compositions for intracellular delivery of therapeutic agents
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Compounds and compositions for intracellular delivery of therapeutic agents
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
Hydrogen sulfide donor in organic salt form and preparation method therefor
A hydrogen sulfide donor in an organic salt form and a preparation method thereof. The hydrogen sulfide donor exists as a salt formed by organic compounds with an alkaline motif and hydrogen sulfide with weak acidity. The hydrogen sulfide donor features with a simple structure, and an easy preparation method. Moreover, hydrogen sulfide donors in different forms can be prepared according to research and development needs. After the hydrogen sulfide donor enters an organism, the process of in vivo dissociation and hydrogen sulfide supply is simple, rapid, and effective, and there is no requirement for enzyme or any other complicated condition, and thus, the hydrogen sulfide donor has a great application prospect and value.
Hydrogen sulfide donor in organic salt form and preparation method therefor
A hydrogen sulfide donor in an organic salt form and a preparation method thereof. The hydrogen sulfide donor exists as a salt formed by organic compounds with an alkaline motif and hydrogen sulfide with weak acidity. The hydrogen sulfide donor features with a simple structure, and an easy preparation method. Moreover, hydrogen sulfide donors in different forms can be prepared according to research and development needs. After the hydrogen sulfide donor enters an organism, the process of in vivo dissociation and hydrogen sulfide supply is simple, rapid, and effective, and there is no requirement for enzyme or any other complicated condition, and thus, the hydrogen sulfide donor has a great application prospect and value.
ALPHA-5 BETA-1 INHIBITORS
The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.